Search Results

You are looking at 1 - 4 of 4 items for

  • Author: E. Tonner x
  • Refine by access: All content x
Clear All Modify Search
E Tonner
Search for other papers by E Tonner in
Google Scholar
PubMed
Close
,
GJ Allan
Search for other papers by GJ Allan in
Google Scholar
PubMed
Close
, and
DJ Flint
Search for other papers by DJ Flint in
Google Scholar
PubMed
Close

We have proposed that growth hormone (GH) and prolactin (PRL) interact to suppress apoptosis in the mammary gland. GH increases insulin-like growth factor-I (IGF-I) synthesis whereas PRL suppresses the production of insulin-like growth factor-binding protein-5 (IGFBP-5) in the epithelial cells, which would otherwise inhibit IGF-mediated cell survival. IGFBP-5 was present in milk from involuting glands at high concentrations (approximately 60 microg/ml) and had a high affinity (8.03 x 10(-10) M) for IGF-I, suggesting an inhibitory effect of IGFBP-5 in the mammary gland. IGFBP-5 was present in the micellar fraction of milk and binds specifically to alpha(s2)-casein. Since alpha(s2)-casein also binds plasminogen and tissue-type plasminogen activator (t-PA), resulting in the conversion of plasminogen to plasmin, and since IGFBP-5 binds to plasminogen activator inhibitor-1 (PAI-1), we investigated whether apoptosis and extracellular matrix (ECM) degradation might be coordinately controlled by GH and PRL possibly acting through IGFBP-5. Litters were removed from lactating rats to initiate involution. Plasminogen activation and t-PA activity were both increased dramatically after 48 h and GH and PRL suppressed this response. By contrast, 17beta-oestradiol, progesterone or corticosterone did not influence either process. An antiserum to IGF-I, which blocked systemic IGF-I effects, failed to inhibit the activation of plasminogen or the increase in t-PA, suggesting that paracrine effects of IGF-I may be more important. Teat-sealing, which led to the accumulation of milk without hormonal changes, also led to increases in plasminogen activation and t-PA activity, suggesting that locally produced factors (of which IGFBP-5 is one) are important in controlling ECM remodelling. We propose that GH and PRL inhibit apoptosis and ECM remodelling by a process that involves the control of IGF-I and PAI-1 availability by IGFBP-5, thus allowing these processes to be tightly coordinated.

Free access
D J Flint
Search for other papers by D J Flint in
Google Scholar
PubMed
Close
,
E Tonner
Search for other papers by E Tonner in
Google Scholar
PubMed
Close
,
J Beattie
Search for other papers by J Beattie in
Google Scholar
PubMed
Close
, and
M Gardner
Search for other papers by M Gardner in
Google Scholar
PubMed
Close

Abstract

Lactation was suppressed in rats using a combined treatment of bromocriptine (to reduce prolactin concentrations) and a specific antiserum to rat GH administered twice daily for 2 days. When milk production had ceased, as determined by litter weight loss and the absence of milk in the stomachs of pups, attempts were made to reinitiate lactation using prolactin, GH, insulin-like growth factor-I (IGF-I) precomplexed to recombinant human IGF-binding protein-3 (hIGFBP-3) or IGF-I plus IGF-II precomplexed to hIGFBP-3. Despite the fact that all treatments except prolactin led to increases in serum IGFs and IGFBP-3, only prolactin and GH provoked the reinitiation of milk production as determined by increased litter weight gain, milk in the stomach of pups and a significant increase in the weight of the mammary glands.

Since the mammary gland has been shown to produce IGFBPs which may inhibit IGF action we also tested three IGF-I analogues, R3-IGF-I, Long-IGF-I and Long-R3-IGF-I. R3-IGF-I has a single amino acid substitution (Glu to Arg) at position 3 whereas Long-IGF-I has a 13 amino acid N-terminal extension. These modifications dramatically reduce the ability of these analogues to bind to IGFBPs although they remain active at the IGF-I receptor. Such IGF analogues would therefore be expected to be active irrespective of the production of inhibitory IGFBPs. However, none was effective in reinitiating lactation, even at doses which have been shown to be biologically effective in terms of nitrogen retention.

We therefore conclude that, despite the fact that GH induces increases in serum IGF-I, IGF-II and IGFBP-3 when administered to lactating rats, the combination of all of these factors fails to reinitiate lactation. The biological significance of these changes and the mechanism by which GH stimulates milk secretion, when there appear to be no GH receptors on mammary epithelial cells, remain unclear, although the fact that both GH and prolactin were able to prevent reductions in DNA content of the gland suggest that regulation of apoptosis may be involved.

Journal of Endocrinology (1994) 140, 211–216

Restricted access
D. J. Flint
Search for other papers by D. J. Flint in
Google Scholar
PubMed
Close
,
E. Tonner
Search for other papers by E. Tonner in
Google Scholar
PubMed
Close
,
J. Beattie
Search for other papers by J. Beattie in
Google Scholar
PubMed
Close
, and
D. Panton
Search for other papers by D. Panton in
Google Scholar
PubMed
Close

ABSTRACT

The role of GH was examined using an antiserum to rat GH (anti-rGH). When administered to lactating rats on day 2 of lactation it was without effect, whereas bromocriptine markedly suppressed milk production, with no additional effect of combined treatment. On day 6 of lactation, treatment with anti-rGH was also without effect, whilst bromocriptine again suppressed milk production. Combined treatment, however, suppressed milk synthesis completely, suggesting that GH was capable of maintaining about 50% of normal milk yield in the absence of prolactin at day 6 of lactation. By day 14 of lactation, anti-rGH treatment alone was capable of decreasing milk yield by about 20%, and again milk secretion only stopped completely when GH and prolactin were suppressed. These data suggest that the role of GH in supporting lactation increases as lactation progresses.

The effects of GH in stimulating growth and in increasing milk yield in ruminants have been proposed to be mediated via insulin-like growth factor-I (IGF-I). In rats treated with anti-rGH, both IGF-I and IGF-II were decreased in serum. The concentration of the major IGF-binding protein (IGFBP-3) was not, however, affected by inhibition of GH or prolactin individually, but was decreased in animals treated with bromocriptine and anti-rGH. In animals given both bromocriptine and anti-rGH, concurrent treatment with recombinant bovine GH maintained milk yield at 50% of control values and normalized serum IGF-I, IGF-II and IGFBP-3 concentrations. By contrast, concurrent treatment with IGF-I or IGF-II, despite normalizing their respective concentrations in serum, failed to affect milk yield.

These results suggest that neither IGF-I nor IGF-II is capable of mediating the effects of GH alone. It is, however, possible that they play a part in a coordinated series of responses to GH involving IGF-I, IGF-II and IGFBP-3.

Journal of Endocrinology (1992) 134, 377–383

Restricted access
R M Palmer
Search for other papers by R M Palmer in
Google Scholar
PubMed
Close
,
N Loveridge
Search for other papers by N Loveridge in
Google Scholar
PubMed
Close
,
B M Thomson
Search for other papers by B M Thomson in
Google Scholar
PubMed
Close
,
S C Mackie
Search for other papers by S C Mackie in
Google Scholar
PubMed
Close
,
E Tonner
Search for other papers by E Tonner in
Google Scholar
PubMed
Close
, and
D J Flint
Search for other papers by D J Flint in
Google Scholar
PubMed
Close

Abstract

A polyclonal antiserum to rat GH (anti-rGH) injected into rats for 3 or 8 weeks markedly reduced the weight, total protein and RNA content of muscles of the hind limb. These effects were prevented when bovine GH (bGH) was administered simultaneously.

In a second experiment, the effects of 8 weeks of treatment with anti-rGH on the growth of the whole body, muscle and bone were investigated. Body weights of rats were decreased by 58% by treatment with anti-rGH; muscle weights were reduced by slightly more than the decrease in body weight (by 64%, 65% and 61% respectively for plantaris, soleus and gastrocnemius). The weight of the tibia was decreased by 54%, its length was decreased by 23%, cortical width and overall width were reduced by 26% and 18% respectively, suggesting a possible role for GH in osteoclastic activity.

Serum total insulin-like growth factor-I (IGF-I) concentrations were decreased by 80–90% in both experiments by anti-rGH; these changes were prevented in the first experiment by concurrent treatment with anti-rGH and bGH. The serum IGF-binding protein-3 (IGFBP-3) concentration was also decreased by anti-rGH in experiment 1 (by 86%); the response of the 28-32 kDa IGFBPs was smaller (−35%), and was restored to control values by simultaneous injection of bGH. Western immunoblotting using an antiserum to IGFBP-2 showed that there was a marked decrease from neonatal to adult stages which was independent of anti-rGH treatment. This clearly demonstrated a dissociation of the reciprocal relationship supposed to exist between IGFBPs-2 and -3. The 24 kDa IGFBP-4 was unaffected by anti-rGH but replacement therapy with bGH doubled its concentration.

Although the effects on body and muscle weight were prevented when rats were given anti-rGH and bGH simultaneously, the possibility of mediation by other hormones cannot be precluded.

Journal of Endocrinology (1994) 142, 85–91

Restricted access